New US patent covering Histotype Px® methods granted by the USPTO
OSLO – August 7, 2024 – DoMore Diagnostics, a leader in AI and deep-learning precision medicine for cancer, is pleased to announce that US patent 11,989,882 has been granted by the US Patent and Trademark Office (USPTO).
The newly granted patent is a continuation of US patent 11,361,442 and provides important protection of the novel methods underpinning DoMore Diagnostics’ digital biomarkers including the use of histological image analysis to predict patient outcomes. DoMore Diagnostics holds a global exclusive license to a portfolio of patents and patent applications owned by Oslo University Hospital, covering the intellectual property underpinning Histotype Px and associated machine learning methods.
Torbjørn Furuseth, MD, Co-Founder and CEO at DoMore Diagnostics, commented, "We are delighted to see this continuation patent granted by the USPTO, further broadening the protection of the unique methods associated with our Histotype Px digital biomarkers in one of our key markets. This US patent grant further solidifies our first mover advantage in the rapidly evolving fields of digital pathology and AI-based outcome prediction, consistent with our strategy to vigorously pursue broad IP protection of our key assets and methods.”
About DoMore Diagnostics
DoMore Diagnostics uses artificial intelligence to make personalized treatment decisions simple and accessible for all cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal adenocarcinoma that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.
About Colorectal Cancer and Histotype Px® Colorectal
Colorectal cancer is the third most common and second most deadly cancer but has seen little innovation in diagnostics and treatment the last decades. Adjuvant chemotherapy (ACT) may be provided after primary surgery to prevent the disease from recurring, however overtreatment is prevalent with up to 85% of patients with stage II and stage III not benefitting from ACT and only suffering side effects.
Histotype Px® is an advanced deep learning algorithm that analyzes digital histology slides, identifying patients who may or may not benefit from adjuvant chemotherapy. Data previously published in The Lancet and Lancet Oncology showed the test can accurately predict survival outcomes in colorectal cancer patients. Histotype Px® Colorectal was developed to provide clinicians with valuable information to guide personalized treatment decisions and improve patient outcomes.
For more information about the Histotype Px Colorectal biomarker, please visit:
The Lancet publication.
The Lancet Oncology publication.
Contact:
Torbjørn Furuseth, MD
DoMore Diagnostics
torbjorn.furuseth@domorediagnostics.com